Abstract:
Obesity, dyslipidemia and hypertension are major risk factors for cardiovascular disease and its associated
complications. To evaluate the beneficial effects of sitagliptin and metformin in non-diabetic dyslipidemic and
hypertensive patients. A prospective randomized clinical trial was conducted on 70 newly diagnosed dyslipidemic
patients with BMI ≥ 25 and blood pressure ≥130/80 at outpatient clinic of medical unit-1 of sheikh medical college
/hospital Rahim Yar Khan. They were divided in to three groups each containing 35 patients; First group served as a
healthy control while second and third study groups were given tablet sitagliptin 50mg and tab metformin 850mg
respectively twice a day for twelve weeks. After three months treatment with sitagliptin and metformin there was
significant reduction in body weight (Sitagliptin 6.5% vs Metformin 7.65%) and BMI (Sitagliptin 2.2% vs Metformin
2.8%) with p ≤0.05. Metformin caused a significant reduction in blood pressure with p ≤0.05 (i.e. SBP 9.9% & DBP
6.4%) while sitagliptin caused a highly significant p ≤0.01 reduction in blood pressure (i.e. SBP 15.8% & DBP 12.2%).
There was significant improvement in lipid profile with sitagliptin p≤0.05. The percent reduction in value of TC, TG and
LDL-C was 20.2%, 13.8% and 23.7% while HDL-C value was increased 11.2% respectively. There was highly
significant improvement in lipid profile with metformin p≤0.01. The percent reduction in value of TC, TG and LDL-C
was 27.8%, 28.2% and 40.4% while HDL-C value was increased 16.8% respectively. Both drugs improve
cardiometabolic risk factors independently in non-diabetic patients
